New, targeted lung cancer treatment with splicing-modifying antisense oligonucleotides
A lead splicing-modifying antisense oligonucleotide (AON) locally delivered to the lungs of different mice models of lung cancer effectively reduces tumor growth in vivo. The lead AON could be applicable to the targeted treatment of lung adenocarcinoma, lung squamous cell carcinoma, breast, liver, prostate, colon, cervix and other tumor types displaying...
Inventor(s): Juan Valcarcel, Jordi Hernandez Ribera, Elias Bechara
Keywords(s): Oncology, RNA Modulation Technologies, Spliceosome / Splicing
Category(s): Biotechnology, Drug Targets & Mechanisms, Therapeutics (Biologics & Compounds)
Method to identify new cancer drug targets in spliceosomal components
A new method and tools to map functional interactions of spliceosomal components accurately captures known, and identify new physical and functional associations important for health and disease.The method can be used to infer targets for alternative splicing regulation, and to study the effects on splicing of compounds directed to altered, or disease-associated...
Inventor(s): Juan Valcarcel, Juan Tejedor Vaquero, Panagiotis Papasaikas
Keywords(s): Algorithms, Bioinformatics, Genomics, Oncology
Category(s): Methodology, General Biology & Chemistry, Software & Algorithms